Physician profile
Bela Patel
NPI 1255593901
$2,480.60
in general payments reported to CMS, 2019-2025
21 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $114 · 2021: $732 · 2022: $560 · 2023: $458 · 2024: $398 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,074.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $603.28 | 2020-2025 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $302.34 | 2020-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.85 | 2020-2024 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $208.58 | 2021-2025 | |
| Glaxosmithkline, LLC. | $151.80 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $143.57 | 2021-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $120.07 | 2020-2022 | |
| Abbvie INC. | $96.31 | 2022-2025 | |
| Exact Sciences Corporation | $80.81 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $77.38 | 2021-2025 | Repatha, Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $75.89 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $68.72 | 2021-2022 | |
| Dexcom, INC. | $67.35 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $63.76 | 2021-2023 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $46.54 | 2024 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $36.04 | 2021 | |
| Sanofi-Aventis U.S. LLC | $33.70 | 2022-2023 | |
| United Therapeutics Corporation | $24.88 | 2024 | Tyvaso |
| Pfizer INC. | $20.28 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bela Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.